Navigation Links
Large study finds ICS therapy reduces pneumonia mortality
Date:4/15/2011

Patients with chronic obstructive pulmonary disease (COPD) who are hospitalized for pneumonia and treated with inhaled corticosteroids (ICS) have decreased mortality when compared to those who are not treated with ICS, according to a retrospective analysis of almost 16,000 COPD patients admitted to VA hospitals.

The results were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read the original study here.

The use of ICS in COPD patients reduces exacerbations, but increases the rate pneumonia. "It was therefore believed that it also increased mortality," said Eric Mortensen, MD, investigator at VERDICT (Veterans Evidence-based Research, Dissemination, and Implementation Center, a VA Health Services Research and Development program) and principal investigator on the study. "This was the first large rigorous study to examine whether this was in fact the case."

"This result is the opposite of what many experts have believed," said Dr. Mortensen. "We do, however, believe that this represents the reality because ours is one the largest studies, and employed a rigorous definition of pneumonia that previous studies did not."

Dr. Mortensen and colleagues examined the medical records of 15,768 COPD patients over the age of 65 who had been admitted to the VA hospitals for pneumonia between 2002 and 2007. About half of those patients had been treated with ICS (52.5 percent) and half were not (47.5 percent).

When they analyzed all-cause mortality of the two groups for both 30- and 90-day intervals, there were significant differences between the groups: for 30-day mortality, 10.2 percent of ICS users died, compared to 13.6 percent of those who were not treated with ICS. For 90-day mortality, the difference was even more striking: 17.3 percent among the ICS users died, and 22.8 percent of those who didn't receive ICS.

Overall, those who were not treated with ICS had about a 25 percent greater mortality risk than those who were treated with ICS.

"These results have clear implications for current clinical practice, which has been informed in the past by a series of studies that found an increased risk of pneumonia with ICS use," said Dr. Mortensen. "In contrast, our study would suggest that ICS use may confer a survival benefit to these patients and may be employed when there are not contraindications. These results should reassure clinicians that they can give their COPD patients ICS without fearing that the increased risk of pneumonia will translate into higher risk of mortality."

The next "really big question," according to Dr. Mortensen is whether ICS might be useful to initiate in certain sub-populations hospitalized with pneumonia. "There is currently a large randomized, controlled trial getting started that is looking at using oral versus intravenous steroids for all pneumonia patients," Dr. Mortensen explained. "The potential question is if this is successful would it be as useful to start these patients on inhaled (rather than oral or intravenous) steroids."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Effects of a large reduction in alcohol prices on mortality in Finland
2. Large weight gain raises risk for recurrence among breast cancer survivors
3. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
4. Nick Jonas Lives Large, Despite Diabetes
5. Largest study of high-deductible health plans finds savings, less preventive care
6. Stem Cell Therapy Shrinks Enlarged Hearts
7. Apnea may be cause for awakening and voiding for those with enlarged prostates report Ben-Gurion U.
8. New report says large proportion of colorectal cancer deaths could be prevented
9. PSA screening declines following publication of large trials, guidelines
10. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
11. Childrens Hospital of Orange County receives largest gift in hospital history
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its ... partner for the Tamika Catchings Legacy Tour that will commemorate the Indiana ... hardwood basketball surfaces in all forms and levels of the game, Connor Sports has ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, ... biologics, consumer health and global clinical supply services, today announced two key appointments ... company’s continued investment and strategic growth plans in the Asia Pacific region. , ...
(Date:5/26/2016)... ... ... effort to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is ... the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of ... Mohebi says, “The positive response to the Snapchat videos we started last month has been ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
Breaking Medicine Technology: